{
  "id": 13407505,
  "title": "LB Pharmaceuticals presents data on LB-102 at ECNP congress",
  "url": "https://urgent.news/2026/10/10/lb-pharmaceuticals-presents-data-on-lb-102-at-ecnp-congress",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-10T12:04:41.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/lb-pharmaceuticals-presents-data-on-lb102-at-ecnp-congress-93CH-4942090"
  },
  "original_language": "en",
  "account": "LB Pharmaceuticals Inc (NASDAQ:LBRX) exhibited four posters detailing its research on LB-102 at the 39th European College of Neuropsychopharmacology Congress in Munich, Germany. The presentations covered the drug's mechanism of action, pivotal Phase 3 trials for schizophrenia and bipolar depression, cognitive performance in schizophrenia, and ongoing trials.\n\nThe preclinical study illustrated that LB-102 can modulate dopamine signaling in rat nucleus accumbens by engaging pre-synaptic D2 autoreceptors. This action increases dopamine neurotransmission by attenuating autoreceptor-mediated inhibition of dopamine release. A poster showcased dose-dependent improvements in the Global Cognition composite score from the Phase 2 NOVA-1 trial in schizophrenia patients, with the post hoc analysis concluding that the cognitive benefit was a direct effect of LB-102.\n\nThe company unveiled details of its ongoing pivotal Phase 3 NOVA-2 trial and open label extension NOVA-3 trial, which aim to assess LB-102's efficacy, safety, and long-term effectiveness as a once-daily treatment for adults with schizophrenia. An e-poster introduced the design of the ongoing Phase 2 ILLUMINATE-1 trial, examining LB-102's efficacy and safety in adults with bipolar depression when used as monotherapy. LB-102 is a small molecule under development for various neuropsychiatric disorders, and the company revealed positive data from a Phase 2 schizophrenia trial in early 2025.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}